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Research
AbstrACt
Objectives To find determining factors for persistent 
infarction signs in patients with transient ischaemic 
attack (TIA), herein initial diffusion lesion size, visibility on 
apparent diffusion coefficient (ADC) or fluid-attenuated 
inversion recovery (FLAIR) and location.
Design Prospective cohort study of patients with clinical 
TIA receiving 3T-MRI within 72 hours of symptom onset 
and at 8-week follow-up.
setting Clinical workflow in a single tertiary stroke centre 
between February 2012 and June 2014.
Participants 199 candidate patients were recruited, 
64 patients were excluded due to non-TIA discharge 
diagnosis or no 8-week MRI. 122 patients completed the 
study.
Primary outcome measures The primary outcome was 
visible persistent infarction defined as 8-week FLAIR 
hyperintensity or atrophy corresponding to the initial 
diffusion-weighted imaging (DWI) lesion.
results 50 patients showed 84 initial DWI lesions. 29 
(35%) DWI lesions did not result in infarction signs on 
8-week FLAIR. 26 (90%, P<0.0001) reversing lesions were 
located in the cortical grey matter (cGM). cGM location (vs 
any other location) strongly predicted no 8-week infarction 
sign development (OR 0.02, 95% CI 0.001 to 0.17) or 
partial lesion area decrease (>30% of initial DWI-area, OR 
14.10, 95% CI 3.61 to 54.72), adjusted for FLAIR-visibility, 
DWI-area, ADC-confirmation and time to scan (TTS) from 
symptom onset to baseline MRI. Acute FLAIR-visibility was 
a strong associated factor for persistent infarction signs 
(OR 33.06, 95% CI 2.94 to 1432.34). For cGM lesions area 
size was sole associated factor for persistent infarction 
signs with a 0.31 cm2 (area under the curve (AUC), 0.97) 
threshold. In eight (16%) DWI-positive patients, all lesions 
reversed fully.
Conclusions 16% of DWI-positive patients and one-
third of acute DWI lesions caused no persistent infarction 
signs, especially small cGM lesions were not followed by 
development of persistent infarction signs. Late MRI after 
TIA is likely to be less useful in the clinical setting, and it is 
dubious if the absence of old vascular lesions can be taken 
as evidence of no prior ischaemic attacks.
trial registration number NCT01531946; Results.
IntrODuCtIOn 
The risk of recurrent events including 
devastating stroke after transient isch-
aemic attack (TIA) remains substantial.1 2 
Recently, it was shown that the presence of 
a diffusion-weighted imaging (DWI) lesion 
combined with clinical findings enhanced 
prediction of post-TIA stroke risk compared 
with clinical findings alone.3–5 Even small 
vascular brain lesions below 3 mm were associ-
ated with increased risk of stroke and death.6 
In patients with TIA, DWI lesions are reported 
in 25%–50%.4 5 7–11 Also, the time to baseline 
MRI varies from within 24 hours to 3 weeks 
from symptom onset.12 A recent meta-anal-
ysis found that the up to sevenfold variation 
in DWI-positivity rates in patients with clin-
ical TIA remains largely unexplained despite 
attempts to control for factors as varying time 
to MRI.12 Among patients with clinical isch-
aemic stroke, one-third is DWI-negative, but 
their long-term outcome and recurrence rates 
did not differ from DWI-positive patients.13 
Pioneering studies found that patients 
with apparent DWI lesion reversal had 
shorter symptom duration than patients 
with persistent infarction signs14 and noted 
strengths and limitations of this study
 ► Prospective inclusion cohort study of patients with 
clinical transient ischaemic attack evaluated by 
senior consultant stroke neurologists.
 ► Patients received standardised baseline and 8-week 
follow-up MRI in clinical workflow.
 ► National electronic registers provided long-term 
follow-up.
 ► Small lesions below 3 mm were included as they are 
associated with increased risk of stroke and death.
 ► Main limitations are sequence resolution and small 
lesion size.
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absence of persistent infarction signs in a fraction of 
initially DWI-positive patients on chronic phase MRI.14 15 
Lesions with persistent infarction signs were larger and 
had lower apparent diffusion coefficient (ADC) values.15 
A recent series of mixed TIA and minor stroke patients 
found only 6% of initially DWI-positive patients showed 
no lesion on T2-fluid-attenuated inversion recovery 
(FLAIR) images obtained 1–3 months later.16 Despite 
small numbers the absent lesions seemed primarily 
located in cortical grey matter (cGM),16 suggesting that 
acute DWI reversal may be related to the proximity of 
leptomeningeal collaterals.17 18 Cortical perfusion is 
higher than white matter (WM) perfusion, even though 
the ratio declines with age.19 The impact of the under-
lying vascularity is also highlighted in a perfusion study 
of initially DWI-negative patients with clinical time-
based TIA. Patients with initial focal or territorial perfu-
sion abnormalities showed increased rates of new DWI 
lesions on 3-day follow-up compared with patients with 
no perfusion abnormalities.20 Animal imaging studies 
of transient ischaemia with subcortical DWI lesion have 
shown apparent 10-week T1-signal and T2-signal normali-
sation while histology showed selective neuronal loss and 
gliosis.21 Persistent signal changes most likely correspond 
to pannecrosis. A recent 7T in vivo human study showed 
the presence of likely cortical microinfarcts with similar 
MRI appearance compared with microinfarcts on ex vivo 
brain slices with histopathological correlate.22 Although 
the clinical significance of persistent infarction signs is 
unclear, it is well known that numerous cerebral infarcts 
gathered over time are predictive of poor outcome6 
and cognitive decline,23 rendering it of potential patho-
physiological and clinical importance to investigate 
what determines the formation of persistent infarction 
signs. Clinical MRI may not be able to detect all acute 
or chronic ischaemic changes13; yet DWI and T2-FLAIR 
are the most commonly used tools for ischaemia assess-
ment.24 We hypothesised that lesion size, ischaemic depth 
and location are factors likely to predict the occurrence 
of infarction signs after acute ischaemia in clinical TIA.
We aimed to investigate in a clinical setting which char-
acteristics were associated with persistent infarction signs 
8 weeks after DWI-positive TIA, including lesion location, 
size, initial ADC and FLAIR visibility, TIA aetiology and 
clinical risk factors. The ultimate aim was to establish if no 
development of persistent infarction signs after DWI-pos-
itive TIA occurred with a clinically significant frequency.
MethODs
We investigated a prospective patient cohort with clinical 
TIA included after informed consent.
Clinical methodology
We included patients with TIA or minor stroke defined 
as an episode of acute focal neurological symptoms of 
vascular origin25 with resolution within 24 hours.26 We 
defined resolution as National Institutes of Health Stroke 
Scale score of 0 within 24 hours. Senior consultant stroke 
neurologists clinically evaluated and included patients 
with a history and clinical findings consistent with TIA 
February 2012–June 2014. Exclusion criteria were TIA 
(G45.9) not final clinical diagnosis, thrombolysis treat-
ment, MRI contraindications and severe illness likely to 
preclude follow-up. Definitions of clinical risk factors 
are presented in online supplementary methodology. 
Risk factors of stroke, ABCD227 and Trial of Org 10172 
in Acute Stroke Treatment (TOAST)28 classification 
were recorded. All patients were treated with antithrom-
botics and other pharmacological secondary prevention 
according to guidelines.
Mr imaging
We performed 3T-MRI (Siemens Magnetom Verio, 
Siemens, Erlangen, Germany) with a 32-channel head 
coil (Siemens, Erlangen, Germany) including DWI and 
T2-FLAIR imaging after routine stroke protocol within 
72 hours from symptom onset29 and at 8-week follow-up 
to visualise persistent infarction signs. The diffusion 
protocol was single-shot spin-echo diffusion echo planar 
imaging with 220 mm field of view (FOV), 254 mm axial 
0 mm gap slices, b-value 1000 s/mm2 along three orthog-
onal directions; TR/TE 6600/100 ms, acceleration 
factor R 2, matrix size 192×192. The T2-FLAIR protocol 
was 240 mm FOV, 274 mm axial 0 mm gap slices, TR/TE 
6500/133 ms, TI 2134 ms, acceleration factor R 2, matrix 
size 256×256.
Image reading was performed as visual inspection in 
a clinical setting using the PACS without external soft-
ware. Image analysis had two steps: first, we created an 
image template consisting of literature-based examples 
of the scoring categories employed and a case report 
form (CRF). Two blinded certified consultant neurora-
diologists (IH, AFC) tested template and CRF on 50 
randomly chosen cases from the cohort, reading first 
independently, followed by a joined re-evaluation of the 
cases. A consensus-based use of the reading tools was thus 
achieved enabling the use of one reader for consistence 
and reproducibility in assessing the often small lesions. 
Subsequently, one reader (IH), blinded to clinical data 
except for the referral, systematically evaluated the 
cohort’s scans.
In a random 10% sample (defined by date of birth 
as 4th, 14th and 24th day in any month), we calculated 
Cohen’s kappa for intraobserver variation using two CRF 
readings, except for area measurements, with 3 months 
interval and observed a substantial intraobserver agree-
ment (κ=0.80).
Definitions of post hoc vascular findings are presented 
in online supplementary methodology.
Definitions of lesions, size and localisation
We used coregistration marking each lesion with two 
perpendicular intrathecal diameters to ascertain lesion 
localisation between sequences and baseline and 8-week 
MRI. Two separate lesions must not have confluent gliosis. 
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As proxy for lesion size, we used largest lesion area on one 
slice measured by manual regions of interest (ROIs).30 
On baseline MRI, we scored for presence or absence of 
DWI lesions, ADC-confirmation and T2-FLAIR hyperin-
tensities, and divided lesion localisation into WM, cGM 
and deep grey matter (dGM) (basal ganglia). cGM lesions 
may have a minor subcortical WM component.
We defined persistent infarction signs as presence 
of T2-FLAIR hyperintensity24 31 or atrophy in the initial 
DWI-lesion area on 8-week MRI.15 16 32 Absence of 
8-week T2-FLAIR hyperintensity or atrophy in the initial 
DWI-lesion area was defined as no persistent infarction 
signs (figure 1); lesion area decrease was defined as 30% 
or more lesion area reduction. Due to small lesion size, 
this definition was modified from the 10% reduction used 
in ischaemic stroke.33 Lesion area change was graded at 
30%, 50% and 100%.
After collecting all initial and 8-week clinical and radio-
logical data, we checked if DWI lesion site and symptoms 
matched—which it did in all cases—under the supervi-
sion of a senior stroke consultant (HC).
recurrence and follow-up
All patients had a scheduled 8-week telephone 
follow-up34 35 by a doctor to assess self-reported func-
tional status and recurrence of new stroke or TIA. Stan-
dard 3-month follow-up was a face-to-face interview with a 
trained nurse assessing functional status, changes in risk 
factor status and medication adherence. National elec-
tronic patient files provided long-term follow-up informa-
tion on new vascular events.
statistics
For categorical data, we used Fisher’s exact test and 
Mann-Whitney U test for population comparison. For 
dichotomised outcomes, we performed a general linear 
model-based forced entry logistic regression analysis; P 
values were calculated with the Wald test. We included 
lesion location, DWI-lesion size (cm2), visibility on 
baseline ADC or FLAIR and time to baseline MRI as 
parameters in the multivariate analysis. We performed a 
likelihood ratio test for model fit versus an empty model. 
We used receiver operating characteristic (ROC) anal-
ysis for binary classification. Recurrent cerebrovascular 
events were studied using Kaplan-Meier curves and Cox 
Proportional Hazard Model. We considered P values less 
than 0.05 significant. We used R (V.3.2.0), 2015 The R 
Foundation for Statistical Computing, Vienna, Austria, 
URL: http://www. R- project. org/ and SPSS (V.22.0) statis-
tical software, IBM.
results
We included 122 patients with clinical TIA (figure 2), 
median (IQR) age of 65 (54–71) years and median (IQR) 
ABCD2 4 (3–5) (table 1). The median (IQR) time from 
Figure 1 Lesions with and without 8-week infarction signs. Two cortical grey matter lesions are shown on initial diffusion-
weighted imaging (DWI) (A), apparent diffusion coefficient (ADC) (B), initial fluid-attenuated inversion recovery (FLAIR) (C) and 
8-week FLAIR (D). (A) Both lesions are DWI-positive. (B) The medial lesion is ADC-confirmed, the lateral lesion shows no ADC-
confirmation. (C) Both lesions are initially FLAIR-positive. (D) The medial lesion is 8-week FLAIR-positive, the lateral lesion is 
8-week FLAIR-negative.
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ictus to initial MRI (TTS) was 31.5 (23.5–56.8) hours. 
Table 1 shows the patients’ baseline characteristics and 
findings on subacute DWI and 8-week T2-FLAIR. Fifty 
patients showed 84 DWI lesions. Thirty-two patients had 
solitary DWI lesions. Thirty-three lesions were located in 
WM, 47 lesions in cGM and 4 lesions in dGM. There were 
no statistically significant relations between DWI-positivity 
rates and time to scan.
Initial DWI lesions located in cGM were less likely to show 
subsequent infarction signs on 8-week MRI (P<0.001, OR 
0.07, 95% CI 0.01 to 0.27) compared with other locations. 
This finding persisted when including only ADC-con-
firmed lesions (22 with no persistent infarction signs, 
hereof 19 (86%) in cGM, P<0.001), or only lesions with 
subacute FLAIR-visibility (13 with no persistent infarc-
tion signs, hereof 12 (92%) in cGM, P<0.001, figure 3). 
Lesions with persistent infarction signs were signifi-
cantly larger than lesions with no persistent infarction 
signs; DWI lesions leading to permanent infarction signs 
ranged 0.05–5.88 cm2 with median (IQR) 0.40 (0.13–
0.86) cm2 and lesions with no permanent infarction signs 
ranged 0.03–1.10 cm2 with median 0.16 (0.08–0.22) cm2, 
P<0.001 (online supplementary table 1). In multivariate 
analysis, cGM location (cGM vs other locations), strongly 
predicted no persistent infarction signs (OR 0.02, 95% CI 
0.001 to 0.17), whereas initial FLAIR-visibility predicted 
subsequent infarction signs (OR 33.06, 95% CI 2.94 to 
1432.34). Initial DWI-lesion size, ADC-confirmation and 
TTS did not reach significance.
If the initial DWI lesion was located in cGM, no initial 
FLAIR-negative or ADC-negative lesions resulted in 
persistent infarction signs, but persistent infarcts were 
visible for 64% (21/33) of initially FLAIR-positive and 
53% (21/40) of ADC-confirmed cGM lesions. Size of 
cGM lesions was the single associated factor for persistent 
infarction signs with an optimal area threshold 0.31 cm2 
(AUC 0.97, online supplementary figure 1) to discern 
between lesions with or without 8-week infarction signs.
Figure 4 shows change of lesion size between base-
line and 8-week MRI stratified according to tissue type. 
Of the initial 84 DWI lesions, 51 (61%) lesions showed 
at least 30% lesion area decrease and 15 (18%) showed 
lesion area increase of 30% or more. WM lesions had 
the highest rate of area increase, 13/33 (39%) and the 
highest degree of increase. We found that 41/47 (87%) 
of the lesions located in cGM decreased in size and 26/47 
(55%) completely vanished leaving no persistent infarc-
tion signs (figure 4). Adjusted for ADC-confirmation, 
initial FLAIR-visibility and DWI-lesion size cGM location 
(cGM vs other locations) was a strong associated factor 
of lesion area decrease (OR 14.1, 95% CI 3.61 to 54.72). 
The distribution of lesions with area decrease or increase 
differed significantly between cGM and WM (P<0.0001, 
online supplementary figure 2).
To assess if individual patients retain persistent infarc-
tion signs after having at least one DWI-positive lesion, 
we defined lesion burden as the sum of each patient’s 
combined DWI areas. Sixteen per cent of DWI-positive 
patients showed no persistent infarction signs (table 1). 
Only the combined sum of DWI-lesion areas significantly 
predicted persistent infarction signs. There was a signif-
icant correlation (OR 1.20 per additional mm2, 95% CI 
1.11 to 1.28) between the patients’ total DWI area and 
the probability of persistent infarction signs. There was 
no significant correlation between increasing ABCD2 
score and the probability of persistent infarction signs 
(OR 1.09, 95% CI 0.82 to 1.46).
Eight weeks post-TIA we found no correlation 
between persistent infarction sign presence and 
patient-reported return to pre-TIA daily activity level 
(4 (33%) vs 35 (36%), P=0.87). Fourteen recurrent 
cerebrovascular events occurred during the median 
(IQR) follow-up period of 817 (440–1056) days. Char-
acteristics of patients with recurrent ischaemic event 
are presented in online supplementary table 2. Ipsi-
lateral carotid stenosis ≥70% (HR 7.11, 95% CI 1.98 
to 25.5) and several competing TOAST aetiologies 
(HR 3.74, 95% CI 1.13 to 12.4) predicted recurrent 
ischaemic events (online supplementary figure 3). 
Persistent 8-week infarction signs (HR 0.50, 95% CI 
0.14 to 1.78) did not increase the risk of recurrent 
events.
Figure 2 Strengthening the Reporting of Observational 
Studies in Epidemiology diagram of patient flow, inclusion 
and exclusion. Other non-ischaemic comprises patients 
with peripheral nerve compression (2), ophthalmological 
symptoms (2), trigeminal neuralgia (1), normal pressure 
hydrocephalus (1), hyperventilation (1), paraesthesia 
secondary to anaemia (1), peripheral extremity embolus (1), 
food poisoning (1) and secondary refusal (1). TIA, transient 
ischaemic attack; tPA, tissue plasminogen activator.
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DIsCussIOn
Sixteen per cent of initially DWI-positive patients and 
one-third of identified lesions show no sign of infarction 
8 weeks later; cGM location was the strongest associated 
factor of full recovery on MRI at 8 weeks, and cGM DWI 
lesions smaller than 0.31 cm2 did not show persistent 
infarction signs. ADC confirmation or subacute FLAIR 
visibility did not in all cases result in visible long-term 
infarction signs.
Ischaemic lesions decreased in size after early intra-ar-
terial revascularisation17 and cortical lesion sparing in 
middle cerebral artery territory infarctions was related to 
Table 1 Patient characteristics 
All 8 weeks
Eight-week 
infarct No infarct  P OR (95% CI)
All patients 122 43 79
Female sex, n 52 (43%) 15 (35%) 37 (47%) 0.251* 0.61 (0.28 to 1.31)
Age, median (IQR) 65 (54–71) 60 (53–70) 65 (55–74) 0.228† –
Medical history
  Prior stroke 22 (18%) 6 (14%) 16 (20%) 0.466* 0.64 (0.23 to 1.78)
  Prior TIA 12 (10%) 7 (16%) 5 (6%) 0.111* 2.87 (0.85 to 9.70)
  Prior MI 9 (7%) 2 (5%) 7 (9%) 0.491* 0.50 (0.10 to 2.53)
  Atrial fibrillation 12 (10%) 7 (16%) 5 (6%) 0.111* 2.89 (0.85 to 9.70)
  Hypertension 60 (49%) 26 (60%) 34 (43%) 0.088* 2.02 (0.95 to 4.31)
  Diabetes 16 (13%) 8 (19%) 8 (10%) 0.261* 2.03 (0.70 to 5.86)
  Depression 14 (11%) 7 (16%) 7 (9%) 0.244* 2.00 (0.65 to 6.14)
  Current smoking 43 (35%) 18 (42%) 25 (32%) 0.324* 1.53 (0.71 to 3.30)
  Alcohol overuse 12 (10%) 5 (12%) 7 (9%) 0.754* 1.32 (0.39 to 4.43)
  Antiplatelet use 40 (33%) 13 (30%) 27 (34%) 0.692* 0.84 (0.38 to 1.86)
  Warfarin 2 (2%) 1 (2%) 1 (1%) 1.000* 1.86 (0.11 to 30.5)
Index TIA
  ABCD2 4 (3–5) 4 (3–5) 4 (3–5) 0.485† –
  Symptom duration 0.852*
  <60 min 58 21 (36%) 37 (64%) 1.00
  >60 min 64 22 (34%) 42 (66%) 0.93 (0.44 to 1.94)
Imaging findings
  TTS (hours) 32 (24–57) 41 (22–66) 29 (24–50) 0.367† –
  DWI-positive 50 42 (84%) 8 (16%) <0.0001* NA
  Sum of DWI-lesion area, cm2 0.41 (0.21–1.08) 0.53 (0.31–1.22) 0.09 (0.07–0.22) <0.0001† –
  Ipsilateral cervical carotid stenosis 5 (4%) 1 (2%) 4 (5%) 0.656* 0.45 (0.05 to 4.13)
  Contralateral cervical carotid 
stenosis
6 (5%) 1 (2%) 5 (6%) 0.522* 0.35 (0.04 to 3.12)
  Ipsilateral intracranial stenosis‡ 9 (12%) 1 (4%) 8 (17%) 0.144* 0.19 (0.02 to 1.63)
  Contralateral intracranial stenosis‡ 1 (1%) 0 (0%) 1 (2%) 0.450* NA
TOAST aetiology 0.727*
  Small vessels 49 16 (33%) 33 (67%) 1.00
  Large vessels 28 12 (43%) 16 (7%) 1.55 (0.59 to 4.03)
  Cardiogenic 18 5 (28%) 13 (72%) 0.79 (0.24 to 2.61)
  Multiple possible aetiologies 27 10 (37%) 17 (63%) 1.21 (0.45 to 3.24)
  TTF (days) 56 (55–60) 55 (55–60) 56 (55–60) 0.832† –
*Fisher’s exact test.
†Mann-Whitney U test.
‡CTA or TCD available in 75 patients, hereof 28 with 8-week infarction signs.
CTA, CT angiography; DWI, diffusion-weighted imaging; MI, myocardial infarction; NA, not applicable; TCD, transcranial Doppler; TIA, 
transient ischaemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; TTF, time to follow-up; TTS, time to scan. 
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collateral perfusion and affected by significant stenosis of 
the ipsilateral anterior or posterior cerebral artery.18 In 
rats early (within 1 day) postischaemic maximum hyper-
perfusion indicated small final lesion size while rats with 
late (4 days) maximum hyperperfusion showed large 
lesions after transient experimental ischaemia,36 indi-
cating rich, tightly webbed collaterals lead to improved 
early reperfusion and limit tissue damage.
Literature holds few and heterogeneous serial MRI 
TIA-related studies with varying populations and rates of 
DWI positivity and reversal. The mixed ‘high-risk TIA’16 
and minor stroke study reported a 6% DWI-lesion reversal 
with imaging performed at a median delay of 13 hours 
after symptom onset. Our cohort only consists of patients 
with symptom duration of less than 24 hours, which may 
explain our larger 16% rate of patients with no persistent 
infarction signs. Our TTS and per patient DWI posi-
tivity and reversal rates correspond to the smaller time-
based TIA study.15 Our cohort’s 31 hours median delay to 
imaging may explain why several lesions are FLAIR-posi-
tive representing the beginning vasogenic oedema, and 
the persistent ADC-reduction represents the still active 
cytotoxic oedema.37 We found no association between 
DWI-positivity rate and time to scan in line with recent 
meta-analysis.12
In TIA, DWI lesions are rarer and smaller and the 
TIA presumably results from smaller occlusive events 
compared with stroke. Changes in perfusion and 
Figure 3 Probability of permanent infarction signs stratified by anatomical location. DWI-lesion location in the cortical grey 
matter was significantly less likely to show permanent infarction signs. *P<0.001 against other anatomical location. ADC, 
apparent diffusion coefficient; cGM, cortical grey matter; dGM, deep grey matter; DWI, diffusion-weighted imaging; FLAIR, fluid-
attenuated inversion recovery; WM, white matter. 
Figure 4 Decrease and increase of lesion size between admission MRI and 8-week follow-up MRI for all lesions and stratified 
according to lesion localisation into white matter (WM), cortical grey matter (cGM) and deep grey matter (dGM).
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underlying vascularity reflect tissue vulnerability and 
damage. This study indicates that ischaemic tissue damage 
in TIA is heterogeneous and differs with lesion localisa-
tion, which may mirror the inherent difference between 
end-artery dominated WM and cGM with proximity to 
leptomeningeal collaterals. This and smaller lesion size 
may explain the high variation in DWI-positivity rates 
among TIA populations and the high rate and cortical 
predilection of apparent diffusion lesion reversal in this 
TIA study.
However, in an observational exploratory study, we 
cannot infer causality but hypothesise that the stronger 
leptomeningeal collateral circulation in cGM may prevent 
persistent infarction signs in small lesions.
This study has some limitations. As inclusion was based 
on informed consent, the study was not unselected or 
consecutive. Fourteen per cent (12/84) of the initial 
lesions were small (<3 mm), and below the usual recom-
mended cut-off level to discriminate between lacunes and 
perivascular spaces,38 but we included this type of lesion 
as it has been associated with increased risk of stroke and 
death.6 Other potential limitations are partial volume 
effects and the 2D-FLAIR sequence in our standard stroke 
MRI-protocol, though its slice thickness is similar to prior 
studies’.15 16Artefacts on T2-FLAIR caused by magnetic 
susceptibility, pulsatile CSF flow or no nulling of the CSF 
signal are common39 and may have masked small lesions. 
Other potential confounders are change and variation in 
FLAIR signal intensity of the lesion40 and our lesion defi-
nition includes atrophy corresponding to the initial DWI 
lesions although this can be difficult to visualise, even 
when aided by T1 and T2, and may explain why lesions 
are not persistently visible.15 32 We lost 10% (13/135) of 
eligible patients for 8-week MRI, this may have caused a 
selection bias. At 3T dedicated high-resolution 3D-FLAIR 
and 3D-T1 could improve differentiation between 
healthy tissue and postinfarction gliosis or atrophy, espe-
cially cortically. While probably not in clinical reach soon, 
higher field strength has shown promising results for the 
in vivo identification of cortical microinfarcts22 and visu-
alised a hereto unseen but probably quite common struc-
tural ischaemic burden.
COnClusIOn
cGM localisation of the acute DWI lesion in TIA was 
a strong associated factor of no persistent infarction 
signs after TIA. Late MRI after TIA may not detect a 
significant number of lesions, especially cortical lesions 
and no prior lesions on the MRI is not evidence of no 
prior ischaemic events. It is yet to be determined if the 
apparent full resolution of brain lesions is related to 
the clinical course including risk of recurrence and 
sequelae of TIA including vascular dementia, fatigue 
and depression.
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